NEW YORK, July 5, 2026, 14:08 EDT
- Pfizer Inc. NYSE:PFE finished the shortened week at $24.32, up just 0.12% from June 26. Volume for the four trading days reached 204.2 million shares.
- Pfizer’s $0.43 quarterly dividend comes out to $1.72 a share annualized, a yield of about 7.1% at Thursday’s close. The company paid out $2.4 billion in Q1 dividends and put $2.5 billion into internal R&D.
- The New York Stock Exchange was shut July 3 for the Independence Day holiday. Pfizer will hold its second-quarter call Aug. 4, its next scheduled investor event.
Pfizer Inc. NYSE:PFE heads into this week after the stock managed to stop the steep drops, though buyers are still scarce. Shares ended Thursday at $24.32, just 3 cents above where they were on June 26. Over the last four sessions, 204.2 million shares moved, good for a 0.12% rise. That volume is around 3.6% of Pfizer’s diluted share count used in Q1 EPS calculations.
The NYSE stayed closed on Friday so the tape didn’t move. The exchange had July 3 as its 2026 Independence Day holiday. July 5 is a Sunday in New York. NYSE core trading runs from 9:30 a.m. to 4 p.m. ET.
This is how trading shaped up in the short week:
| Session | Pfizer close | Day change | Volume |
|---|---|---|---|
| Jun 26 | $24.29 | up 2.62% | 58.6 mln |
| Jun 29 | $24.37 | up 0.33% | 46.1 mln |
| Jun 30 | $24.08 | down 1.19% | 57.6 mln |
| Jul 1 | $23.88 | off 0.83% | 48.7 mln |
| Jul 2 | $24.32 | up 1.84% | 51.8 mln |
Pfizer lagged its rivals Thursday after a 1.84% gain, MarketWatch said. Johnson & Johnson NYSE:JNJ rose 3.57%. Eli Lilly and Co. NYSE:LLY picked up 1.86%. Abbott Laboratories NYSE:ABT was up 3.49%. The S&P 500 ended barely changed and the Dow Jones Industrial Average added 1.14%.
Pfizer is keeping its dividend at $0.43 a share for the third quarter, with payment due Sept. 1 to shareholders on record as of July 24. The company said this will be its 351st consecutive quarterly dividend.
| Measure | Latest figure | Why it matters |
|---|---|---|
| Thursday close | $24.32 | This is the starting point for the yield check |
| Annualized dividend | $1.72/share | Pays $0.43 each quarter |
| Implied yield | 7.1% | Yield is up there for income seekers, also puts growth in question |
| Q1 cash dividends | $2.4 bln | Payout was almost as much as internal R&D cost |
| Q1 internal R&D | $2.5 bln | Puts the focus on pipeline spending |
| 2026 buybacks | None assumed | No lift for EPS from buying back stock |
From an investor view, Pfizer is starting to look less like a growth pharma play and more like a company focused on cash returns. Pfizer paid out $2.4 billion in dividends in the first quarter and spent $2.5 billion on R&D. The company didn’t buy back any shares and has said its 2026 outlook doesn’t count on buybacks.
Chief Financial Officer David Denton said he was “particularly pleased” with 22% operational revenue growth from launched and acquired products. CEO Albert Bourla said he was “particularly encouraged” by results in oncology and obesity. Both executives now need that momentum to convert into cash flow so the company can defend its payout and try to get the stock out of the low-$20s. Q4 CDN
China made some news last week on GLP-1 drugs. Reuters said June 29 that Pfizer and Innovent Biologics HKG:1801 passed a first review for adding their GLP-1 drugs—including Pfizer’s ecnoglutide—to China’s main medical insurance drug list. If included, it could mean lower treatment costs.
The FDA cleared palbociclib, or Ibrance, for use with trastuzumab, with or without pertuzumab, and endocrine therapy as maintenance for adults with HR-positive, HER2-positive advanced or metastatic breast cancer after induction treatment, according to a statement June 24.
Pfizer reported that the PATINA trial cut the risk of progression or death by 24%. Aamir Malik, Pfizer’s chief U.S. commercial officer, said Ibrance is the “first and only CDK4/6 inhibitor” cleared for HR-positive metastatic breast cancer, no matter the patient’s HER2 status. Otto Metzger at Dana-Farber Cancer Institute said the drug can “meaningfully extend the time” patients live without their disease getting worse. Pfizer
No set date yet for Pfizer’s next earnings. The closest scheduled event is an Aug. 4 call with analysts at 10:00 a.m. EDT, with the second-quarter report coming out that morning. Ahead of that, July 24 is the dividend record date, putting a near-term focus on income for the stock.
Related articles: NYSE:PFE
